A stable liquid composition comprising a botulinum toxin as an active ingredient is described, which is ready-to-use without the need for a reconstitution process, and thus, it is possible to improve user's convenience, and reduce a deviation of botulinum toxin activity due to dilution errors in the reconstitution process. Further, the liquid composition efficiently prevents the botulinum toxin from aggregating even at a low botulinum toxin concentration to thereby have extremely excellent storage stability, and efficiently prevents adsorption of the botulinum toxin to a container, thereby constantly maintaining an activity of the botulinum toxin for each batch or for each liquid vial.

Method of treating or reducing a symptom of traumatic brain injury (TBI) in a subject, comprising administering to the subject a therapeutically-effective amount of botulinum neurotoxin. Composition for use in treating or reducing a symptom of TBI in a subject comprising botulinum neurotoxin. Computer system programmed to receive information related to a subject's response to administration of botulinum neurotoxin, store that response in a database, and transmit the response to a medical practitioner. Non-transitory computer-readable storage medium storing instructions that, when executed by a computer system, causes the computer system to perform the aforementioned steps.

Systems and methods for determining a patient treatment plan to prevent or treat wrinkles using a neural network. The method includes receiving, by a computing device, patient data including at least a dynamic index and a static index for at least one muscle group of a patient. The method also includes determining, by the computing device, based on the patient data, a patient treatment plan including at least one dose of a treating compound to be administered to the patient at one or more application locations on the patient. The method further includes providing, by the computing device, the patient treatment plan for use in preventing or treating wrinkles on the patient.

The present invention includes light-controlled and light-independent neurotoxin systems and methods for using such neurotoxin systems for rapidly and locally silencing distinct populations of neurons.

The present invention relates to a liquid formulation containing botulinum toxin and stabilizing agent, and preparation method therefor. A liquid formulation containing botulinum toxin and stabilizing agent according to the present invention can be easily stored and distributed. It was proved a significant effect on the stabilization of botulinum toxin under suitable conditions according to the temperature and pH of the human body. Thus, it is expected that the pharmaceutical composition of the present invention will greatly contribute to the safe and convenient medical use of botulinum toxin.

The present invention is directed to a botulinum neurotoxin serotype E (BoNT/E) for use in treating a disorder, wherein the BoNT/E is administered to a human subject, and provides a maximum inhibition of neurotransmitter secretion from a target cell or tissue in ≤13 days after administration; and reduces to >25% inhibition of neurotransmitter secretion from the target cell or tissue at day 14 after administration.

Microneedle arrays for introducing an active ingredient through a skin surface of a subject can include a base layer, a plurality of microneedles projecting from the base layer, and an active ingredient. Each of the microneedles comprises an elongate body having a proximal portion and a distal portion, in which the proximal portion is attached to the base layer. Each of the microneedles comprises at least one dissolvable polymer. The active ingredient is incorporated in the elongate body, and the active ingredient is present only in the distal portion and at least internally in the distal portion.

The present invention relates to a prefilled plastic container, such as a plastic syringe, comprising an aqueous botulinum toxin formulation. The aqueous botulinum toxin formulation in the prefilled plastic container is stable for a prolonged time period. Furthermore, the present invention relates to a kit comprising the prefilled plastic container, and to the use of the prefilled plastic container for therapeutic and cosmetic purposes.

Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.

The main aspect of present invention is to provide a pharmaceutical composition to increase the stability of liquid formulation of botulinum toxin and related proteins. The present invention provides a method to stabilize toxin in liquid formulation. Lipid based drug delivery system is known to increase the bioavailability of drugs (Amidon et al., 1995; Jannin et al., 2008). We investigated the stability of BoNT/A toxin and complex. We used two formulations in liquid phase: combination of lipids and liposomes, with two different storage conditions: 4° C. and 25° C. The present invention also provides a method for efficient delivery of botulinum toxin through skin as a topical application.